Clinical trials: Hepatitis C Virus
Chronic Hepatitis C
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin…
- Trial name
- REAL (NCT02582658)
- Volunteers
- 173 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir
The purpose of this study is to assess safety, tolerability, pharmacokinetics (how the drug is absorbed into the bloodstream) and antiviral activity of repeated doses of TMC647055 given in combination with telaprevir in HCV…
- Trial name
- NCT01582035
- Testing
- TMC647055, TVR, PegFN
- Where
- 2 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection
- Trial name
- NCT00546715
- Testing
- Daclatasvir
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with…
- Trial name
- POLARIS-3 (NCT02639338)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as…
- Trial name
- PEARL-III (NCT01767116)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 419 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C Virus
TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin
The purpose of this study is to determine in genotype 1 Hepatitis C Virus (HCV)-infected participants, the safety, tolerability, pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and…
- Trial name
- NCT01391117
- Testing
- TMC649128., TMC649128
- Where
- 3 sites in Netherlands, Poland
- Volunteers
- 14 people
- Sponsor
- Tibotec BVBA
Hepatitis C, Chronic, Hepatitis C
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
The objective of the study is to evaluate the costs associated with peginterferon alfa-2b (PegIntron) plus ribavirin (Rebetol) treatment for chronic hepatitis C in the Czech Republic.
- Trial name
- NCT00723632
- Testing
- peginterferon alfa-2b, ribavirin
- Volunteers
- 901 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic Hepatitis C
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, and affect on blood levels of miravirsen and telaprevir when administered together.
- Trial name
- NCT01646489
- Testing
- Miravirsen sodium, Telaprevir
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
Chronic Hepatitis C Infection
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
This is a phase 3, double-blinded, multicenter study. The study will consist of 2 substudies: Substudy 1 (SS1) will be double-blinded and enroll non-cirrhotic subjects and Substudy 2 (SS2) will be open label and enroll subjects…
- Trial name
- GIFT I (NCT02023099)
- Testing
- ABT-450/r/ABT-267
- Volunteers
- 363 people
- Sponsor
- AbbVie
Hepatitis C Virus
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
The purpose of the study is to investigate the effect of moderate and severe hepatic impairment on the pharmacokinetics of TMC435.
- Trial name
- NCT01046058
- Testing
- TMC435
- Where
- 3 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C.
- Trial name
- NCT00800748
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 35 sites in Czechia, Slovakia
- Volunteers
- 372 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing…
- Trial name
- NCT01798576
- Testing
- Pegylated Interferon alfa-2a, Ribavirin
- Where
- Romania
- Volunteers
- 282 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin)…
- Trial name
- NCT01585324
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
- Trial name
- NCT00724776
- Testing
- Albinterferon alfa 2b
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Novartis
Hepatitis C
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.
- Trial name
- NCT01682720
- Testing
- SOF, RBV
- Where
- 77 sites in Austria, Estonia and 8 more
- Volunteers
- 421 people
- Sponsor
- Gilead Sciences
Hepatitis, Hepatitis C
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0 μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin in the treatment of chronic hepatitis C, and to…
- Trial name
- NCT01740089
- Testing
- Algeron, PegIntron, Ribavirin
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Biocad
HCV Infection
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to assess the safety, tolerability and effectiveness of ANA598 when administered with pegylated interferon and ribavirin (Standard of Care [SOC]) compared to placebo + SOC.
- Trial name
- NCT00978497
- Testing
- ANA598, Peginterferon, Ribavirin
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the…
- Trial name
- CONCISE (NCT01459913)
- Testing
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Where
- 83 sites in United States, Austria and 4 more
- Volunteers
- 239 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.